Tapinarof cream safe and effective therapy for long-term in patients with plaque psoriasis

Against the above background, Jerry Bagel, Psoriasis Treatment Center of New Jersey, NJ, USA, and colleagues aimed to assess long-term, health-related quality of life and patient satisfaction with tapinarof, a first-in-class, nonsteroidal, aryl hydrocarbon 131 receptor (AhR) agonist approved by the US FDA (Food and Drug Administration) for plaque psoriasis treatment in adults.

Tapinarof cream 1% once daily had shown significant efficacy and was well tolerated versus vehicle in two 12-week, phase 3 pivotal trials in people with mild to severe plaque psoriasis.

Patients who completed the 12-week trials were suitable for 40 weeks of open-label tapinarof based on PSOARING 3, with a 4-week follow-up. DLQI (Dermatology Life Quality Index) was evaluated at every visit; PSQ (Patient Satisfaction Questionnaire) responses were assessed at week 40 or early termination.

The study led to the following findings:

· 763 eligible patients were enrolled; 78.5% completed the PSQ.

· There was an improvement in DLQI scores which were maintained.

· 68.0% of patients had a DLQI of 0 or 1 by Week 40, suggesting no impact of psoriasis on health-related quality of life.

· Most patients strongly agreed or agreed with all PSQ questions evaluating confidence in tapinarof and satisfaction with efficacy, application ease and cosmetic elegance, and preference for tapinarof versus prior psoriasis therapies.

"Tapinarof cream 1% QD represents a novel, nonsteroidal therapeutic option for patients with plaque psoriasis," the researchers concluded.

Reference:

Bagel J, Gold LS, Del Rosso J, Johnson S, Yamauchi P, Brown PM, Bhatia N, Moore AY, Tallman AM. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. J Am Acad Dermatol. 2023 May 10:S0190-9622(23)00771-5. doi: 10.1016/j.jaad.2023.04.061. Epub ahead of print. PMID: 37172733.